Please login to the form below

Not currently logged in
Email:
Password:

Axelar appoints Carl Harald Janson as CEO

Takes control as company prepares to take novel cancer drug to proof-of-concept

Swedish biotech Axelar has picked former board member Carl Harald Janson to take over from CEO Johan Harmenberg, who will remain at Axelar as chief medical officer.

Janson joins from KDev Oncology, the oncology division of Karolinska Developments, where he also served as CEO, having previously worked as VP portfolio management at Karolinska Development from 2008 to 2011.

“I am excited to lead the experienced team of Axelar and to continue the development of AXL1717. I look forward to take this potential novel cancer treatment to proof-of-concept,” said Janson.

AXL1717 is an inhibitor of the insulin-like growth factor 1 (IGF-1) receptor pathway and Axelar's lead compound and the company says it has potential in a wide range of cancers.

The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II clinical trial with the drug has been completed, demonstrating a good tolerability profile of the compound.

9th October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics